Dose titration patterns, effectiveness and safety of vericiguat in Chinese patients with HFrEF: A real-world study

The Role of Vericiguat in Reversing Ventricular Remodeling in Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Multicenter Cohort Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300076162

Enrollment

Unknown

Registered

2023-09-26

Start date

2023-10-01

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

vericiguat group:NA

control group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Age = 18 years; ? Echocardiography-measured LVEF = 45%; ? NYHA functional class II-IV, with symptoms and signs of heart failure; ? Optimal treatment with pharmacologic and device therapy.

Exclusion criteria

Exclusion criteria: ? SBP < 90 mmHg or presence of symptomatic hypotension; ? Severe renal impairment: eGFR < 15 ml/(min·1.73?); ? Severe hepatic impairment: Child-Pugh C; ? Use of other sGC stimulators or phosphodiesterase-5 inhibitors (PDE-5i); ? Allergy to any sGC stimulator; ? Pregnancy or breastfeeding women; ? Participation in another interventional clinical study and treatment with another investigational drug within 30 days prior to screening.

Design outcomes

Primary

Measure	Time frame
Left ventricular end-diastolic volume;	—

Secondary

Measure	Time frame
Left ventricular end-systolic volume;Left ventricular end-diastolic volume index;Left ventricular end-systolic volume index;Left atrial volume index;Left ventricular ejection fraction;NT- pro BNP;	—

Countries

China

Contacts

Public ContactHuixia Lu

Qilu Hospital of Shandong University

luhuixia@sdu.edu.cn+86 185 6008 6591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026